Journal
CURRENT DRUG TARGETS
Volume 10, Issue 12, Pages 1190-1195Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/138945009789753282
Keywords
Acute kidney injury; acute tubular necrosis; clinical trial design; surrogate endpoint; biomarker
Categories
Funding
- NIH/NCRR/OD UCSF-CTSI [KL2 RR024130]
Ask authors/readers for more resources
Acute kidney injury is associated with significant morbidity and mortality in hospitalized patients. Clinical trials for acute kidney injury have been hampered not only by a paucity of appropriate potential therapeutic agents, but also by several clinical trial design challenges. First, for novel therapies to have the best chance at efficacy, early patient identification is critical. Second, for certain novel therapies with a mechanism of action directed at the underlying disease state (e.g., sepsis) or a specific pathogenic process, careful disease phenotyping may be required. Third, even among patients with AKI, risk stratification may be required to select a higher-risk subset for clinical trials. Finally, clinical endpoints for clinical trials must be considered carefully, as patients may die for reasons unrelated to AKI, including withdrawal of support. However, these challenges are not unique to AKI; some possible solutions including alternative endpoints used in other clinical trial settings are reviewed here.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available